A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

NCT06399757 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Cholangiocarcinoma
Appendiceal Adenocarcinoma
Pancreatic Adenocarcinoma
Gastric Adenocarcinoma
Endometrial Adenocarcinoma
Triple Negative Breast Cancer
Ovarian Cancer
Prostate Cancer

Interventions

DRUG: APL-5125

Sponsor

Apollo Therapeutics Ltd